These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 31179679)

  • 1. Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics.
    Mu W; Jiang D; Mu S; Liang S; Liu Y; Zhang N
    ACS Appl Mater Interfaces; 2019 Jul; 11(26):23591-23604. PubMed ID: 31179679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Zhou F; Shang W; Yu X; Tian J
    Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
    Haruyama Y; Kataoka H
    World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
    Nishimura Y; Nakatsura T; Senju S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
    Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
    Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
    Sun W; Wang Y; Cai M; Lin L; Chen X; Cao Z; Zhu K; Shuai X
    Biomater Sci; 2017 Nov; 5(12):2468-2479. PubMed ID: 29106433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IR780-loaded folate-targeted nanoparticles for near-infrared fluorescence image-guided surgery and photothermal therapy in ovarian cancer.
    Song J; Zhang N; Zhang L; Yi H; Liu Y; Li Y; Li X; Wu M; Hao L; Yang Z; Wang Z
    Int J Nanomedicine; 2019; 14():2757-2772. PubMed ID: 31118609
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma.
    Dhungel B; Andrzejewski S; Jayachandran A; Shrestha R; Ramlogan-Steel CA; Layton CJ; Steel JC
    Gene Ther; 2018 Apr; 25(2):115-128. PubMed ID: 29563582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3 (GPC3) targeted Fe
    Tian R; Zhu L; Qin Z; Wang G; Wang J; Zhang H
    Biomater Sci; 2019 Dec; 7(12):5258-5269. PubMed ID: 31603456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smart NIR-II croconaine dye-peptide for enhanced photo-sonotheranostics of hepatocellular carcinoma.
    Li S; Zhang Y; Liu X; Tian Y; Cheng Y; Tang L; Lin H
    Theranostics; 2022; 12(1):76-86. PubMed ID: 34987635
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
    Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
    Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Specific Isolation and Instant Observation of Circulating Tumour Cell from HCC Patients via Glypican-3 Immunomagnetic Fluorescent Nanodevice.
    Chu Q; Mu W; Lan C; Liu Y; Gao T; Guan L; Fang Y; Zhang Z; Liu Y; Liu Y; Zhang N
    Int J Nanomedicine; 2021; 16():4161-4173. PubMed ID: 34168446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
    Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
    Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
    Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
    Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
    Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
    Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and
    Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
    World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preparation of anti-GPC3 single chain antibody for targeted detection of hepatocellular carcinoma].
    Xiang X; Liu X; Hu Y; Zhao C; Luo W
    Sheng Wu Gong Cheng Xue Bao; 2020 Dec; 36(12):2860-2867. PubMed ID: 33398978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery.
    Tang J; Wang Q; Yu Q; Qiu Y; Mei L; Wan D; Wang X; Li M; He Q
    Acta Biomater; 2019 Jan; 83():379-389. PubMed ID: 30395963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
    Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
    Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.